2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

904. Outcomes Research: Hemoglobinopathies: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Treatment Considerations, Supportive Care, Biological Therapies, Transfusion, Women’s Health, Adverse Events, Clinical Practice (Health Services and Quality), Health Economics, Quality of Care, Diseases, Bleeding and Clotting, Thromboembolism, Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Trait, Thalassemia, Research, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

4434 Ongoing burden of sickle cell disease among individuals treated with newly approved disease-modifying therapies: A real-world claims analysis using United States Medicaid data

Nirmish Shah Jr, MD, Jungyoon Moon, MS2, Vanessa Shih, PharmD3, Jing Zhao, PhD4, Rolandas Urbstonaitis, PharmD5, Sonia Kim, MS6, Hyun Jin Song, PhD7, Junhui Zhao, PhD8, Amber M. Yates, MD9
1 Duke University, Durham, North Carolina, United States
2 Agios Pharmaceuticals, Inc., Cambridge, Massachusetts, United States
3 Agios Pharmaceuticals, Inc., Cambridge, Massachusetts, United States
4 Agios Pharmaceuticals, Inc., Cambridge, Massachusetts, United States
5 Agios Pharmaceuticals, Inc., Cambridge, Massachusetts, United States
6 Genesis Research Group, Hoboken, New Jersey, United States
7 Genesis Research Group, Hoboken, New Jersey, United States
8 Genesis Research Group, Hoboken, New Jersey, United States
9 Agios Pharmaceuticals, Inc., Cambridge, Massachusetts, United States

Introduction: In the United States (US), approximately 100,000 individuals live with sickle cell disease (SCD), many of whom are insured through Medicaid. While hydroxyurea (HU) has been a standard of care, in recent years newer disease-modifying therapies (DMTs) have been approved. There is limited evidence of the clinical burden in patients with SCD receiving the newer DMTs. This study aimed to describe acute complications, healthcare resource utilization (HCRU), and treatment discontinuation patterns in patients with SCD treated with newly approved DMTs and/or HU, and to contextualize HCRU burden relative to a matched non-SCD population.

Methods: This retrospective cohort study used US Medicaid claims data from 1 Jan 2016 to 31 Dec 2022. Eligible patients were identified during the index period (1 Jan 2017 to 31 Dec 2022) and were aged ≥18 years, had ≥1 inpatient (IP) or ≥2 outpatient (OP) claims with an ICD-10-CM diagnosis code for SCD, ≥1 claim for newer DMTs (crizanlizumab, L-glutamine, voxelotor) or HU during the index period, and ≥365 days of continuous Medicaid enrollment prior to cohort entry. Patients with a history of transplant, implausible data, or dual Medicare/Medicaid eligibility were excluded. Patients were categorized into a newer DMT ± HU subgroup or an HU-only subgroup. The index date was the date of first DMT claim for the DMT ± HU subgroup (receiving newer DMTs following or in combination with HU) and the first HU claim for the HU-only subgroup. The baseline period comprised 365 days before index, with no washout applied. Follow-up continued until the earliest of death, Medicaid disenrollment, or study end. A non-SCD cohort was identified using the same inclusion and exclusion criteria (except SCD treatment criterion) and was matched 1:1 to the SCD cohort based on age, sex, race, geographic region, and index year, with index date assigned at a random IP or OP visit during the index period.

Baseline characteristics were summarized descriptively. Acute complications during baseline and follow-up and all-cause HCRU during follow-up were reported as mean events per patient per year (PPPY). Mantel–Haenszel tests for binary outcomes and Poisson generalized estimating equation models for count outcomes were used for HCRU comparisons between SCD patients and matched controls. Median time to discontinuation of the newer DMTs was estimated using the Kaplan–Meier method, with discontinuation defined as a gap of ≥60 days for crizanlizumab and ≥90 days for
L-glutamine and voxelotor.

Results: The study included 10,769 matched pairs in the SCD and non-SCD cohorts: mean age 30 years, 54% female. Within the SCD cohort, median follow-up was 23 months for the newer DMT ± HU subgroup (n=3,804) and 36 months for HU-only (n=6,965). During the baseline period, patients in the newer DMT ± HU and HU-only subgroups experienced acute complications, including vaso-occlusive pain (mean PPPY: 6.4 and 4.7), stroke (0.1 and 0.2), acute renal failure (0.3 and 0.2), and infections (0.9 and 0.7), respectively.

During follow-up, acute complications continued to be observed for the newer DMT ± HU and HU-only groups, including vaso-occlusive pain (mean PPPY: 6.5 and 4.8), stroke (0.1 and 0.2), acute renal failure (0.3 and 0.3), and infections (1.0 and 0.8), respectively. All-cause HCRU (visits PPPY) in the newer DMT ± HU and HU-only subgroups included OP visits (47.0 and 39.0), emergency department (ED) visits (11.3 and 10.0), IP admissions (3.6 and 2.5), and transfusions (1.6 and 1.1), respectively. Compared with matched non-SCD controls, all-cause HCRU PPPY was significantly higher (p<0.001 for all) in the SCD cohort for OP visits (41.1 vs 26.6), ED visits (10.3 vs 1.2), IP admissions (2.8 vs 0.2), and transfusions (1.2 vs 0.03).

Discontinuation of newer DMTs occurred in 69% of crizanlizumab users, 89% of L-glutamine users, and 70% of voxelotor users; median times to discontinuation were 155, 87, and 154 days, respectively.

Conclusions: Medicaid beneficiaries with SCD treated with newer DMTs and/or HU experienced continued clinical burden, reflected in high rates of acute complications and HCRU. HCRU was significantly higher in the SCD cohort compared with matched non-SCD controls, highlighting the substantial burden experienced by this population. Discontinuation of newer DMTs was common and often occurred early after treatment initiation, which may reflect ongoing treatment challenges and persistent unmet needs.

Nirmish Shah Jr, MD: Agios Pharmaceuticals, Inc. - Honoraria; Global Blood Therapeutics - Honoraria; Emmaus Pharmaceuticals - Honoraria; Novo Nordisk - Honoraria; blubird bio - Honoraria; Alexion Pharmaceuticals - Honoraria; Pfizer - Honoraria; Vertex Pharmaceuticals - Honoraria